• Other
  • Exited

Celladon Corporation (NASDAQ: CLDN) is a clinical-stage biotechnology company seeking to correct calcium dysregulation by targeting SERCA enzymes to develop novel therapies for cardiac diseases. The sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) enzymes play an integral part in the regulation of intra-cellular calcium in all human cells. Celladon’s lead candidate MYDICAR, is a genetically targeted enzyme replacement therapy currently in Phase IIb for Systolic Heart Failure (HF), with additional Phase 2a trials in HF and dialysis access beginning in 2014.